Ultragenyx Pharmaceutical (RARE) Reaches $66.75 After 6.00% Up Move, Ohr Pharmaceutical (OHRP)’s Sentiment Is 1.07

July 17, 2017 - By Linda Rogers

Ohr Pharmaceutical, Inc. is a pharmaceutical firm focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The company has market cap of $38.17 million. The Company’s development pipeline consists of several programs and indications at various stages of development. It currently has negative earnings. The Company’s product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% , SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets.

The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is a huge mover today! About 240,493 shares traded. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has declined 6.49% since July 17, 2016 and is downtrending. It has underperformed by 23.19% the S&P500.The move comes after 9 months positive chart setup for the $2.80 billion company. It was reported on Jul, 17 by Barchart.com. We have $70.76 PT which if reached, will make NASDAQ:RARE worth $168.00M more.

Knoll Capital Management Lp holds 0.54% of its portfolio in OHR Pharmaceutical Inc for 204,137 shares. Garrison Bradford & Associates Inc owns 75,700 shares or 0.11% of their US portfolio. Moreover, Sabby Management Llc has 0.1% invested in the company for 1.16 million shares. The California-based Leisure Capital Management has invested 0.09% in the stock. Bailard Inc., a California-based fund reported 449,000 shares.

About 74,373 shares traded. OHR Pharmaceutical Inc (OHRP) has declined 77.87% since July 17, 2016 and is downtrending. It has underperformed by 94.57% the S&P500.

Analysts await OHR Pharmaceutical Inc (NASDAQ:OHRP) to report earnings on August, 8. They expect $-0.25 EPS, down 4.17% or $0.01 from last year’s $-0.24 per share. After $-0.21 actual EPS reported by OHR Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 19.05% negative EPS growth.

Analysts await Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report earnings on August, 14. They expect $-1.73 earnings per share, down 18.49% or $0.27 from last year’s $-1.46 per share. After $-1.63 actual earnings per share reported by Ultragenyx Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 6.13% negative EPS growth.

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $2.80 billion. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. It currently has negative earnings. The Company’s clinical-stage pipeline consists of two product categories: biologics , and small-molecule substrate replacement therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: